院外移动体外生命支持在超机构网络内应用四年经验——160例连续治疗患者结局
该回顾性队列研究分析DELSN网络内2011年7月至2015年10月连续160例接受移动vaECMO的难治性循环衰竭患者(56±16岁,68%在CPR下启动vaECMO),59例(36%)存活至首次出院,中位随访1.74年后50例(31%)仍存活。死亡最集中于最初24小时。存活者与非存活者在年龄、循环衰竭病因、植入时是否CPR或至植入点距离上无差异;非存活者需透析的肾损伤(61% vs 24%,p<0.0001)、休克肝(27% vs 12%,p=0.031)和内脏缺血(19% vs 3%,p=0.013)发生率更高。ECPR与非ECPR亚组结局无显著差异;初始NSE≥45.4μg/L(AUC 0.75,p<0.0001)和乳酸≥5.5mmol/L(AUC 0.70,p<0.0001)时结局显著恶化。
要点
- 160例难治性循环衰竭患者经移动vaECMO治疗,36%存活至首次出院,31%在中位1.74年随访时仍存活。
- 时间离散死亡率在最初24小时内最高。
- 非存活者需透析的肾损伤(61% vs 24%,p<0.0001)、休克肝(27% vs 12%,p=0.031)、内脏缺血(19% vs 3%,p=0.013)发生率高于存活者。
- 初始NSE≥45.4μg/L(AUC 0.75,p<0.0001)和乳酸≥5.5mmol/L(AUC 0.70,p<0.0001)时结局显著恶化。
- ECPR与非ECPR亚组结局无显著差异;存活者与非存活者在年龄、病因、植入时CPR或距离上无差异。
适用人群与场景
- 2011年7月至2015年10月DELSN网络内连续160例难治性循环衰竭接受移动vaECMO的院外患者(56±16岁,68%在CPR下启动vaECMO)。
诊断标准与关键阈值
- 初始神经元特异性烯醇化酶≥45.4μg/L(AUC 0.75,p<0.0001)时结局显著恶化。
- 初始乳酸≥5.5mmol/L(AUC 0.70,p<0.0001)时结局显著恶化。
研究设计与关键结果
- 回顾性队列研究,160例难治性循环衰竭患者连续接受移动vaECMO,59例(36%)存活至首次出院,50例(31%)在中位随访1.74年后仍存活。
- 时间离散死亡率在最初24小时最高。
- 存活者与非存活者在年龄、循环衰竭病因、植入时CPR或至植入点距离上无差异。
- 非存活者需透析的肾损伤发生率61% vs 存活者24%(p<0.0001),休克肝27% vs 12%(p=0.031),内脏缺血19% vs 3%(p=0.013)。
- ECPR与非ECPR亚组结局无显著差异。
- 初始NSE≥45.4μg/L(AUC 0.75,p<0.0001)和乳酸≥5.5mmol/L(AUC 0.70,p<0.0001)时结局显著恶化。
- 项目年份相关的院内死亡率呈上升趋势,而项目年份相关的随访死亡率随时间下降。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:患者选择标准和反映治疗成功或无效的早期结局参数仍需细化。
对床旁实践的改变
- 区域移动ECLS救援治疗可提供令人鼓舞的结局,但患者选择标准和反映治疗成功或无效的早期结局参数仍需细化(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Mobile extracorporeal life support (ECLS) may soon be on the verge to become a fundamental part of emergency medicine. Here, we report on our four-year experience of providing advanced mechanical circulatory support for out-of-center patients within the Düsseldorf ECLS Network (DELSN).
METHODS: This retrospective cohort study analyses the outcome of 160 patients with refractory circulatory failure consecutively treated with mobile veno-arterial extracorporeal membrane oxygenation (vaECMO) between July 2011 and October 2015 within the DELSN.
RESULTS: Out of the 160 patients (56±16years, vaECMO initiation under CPR 68%), 59 patients (36%) survived to primary discharge, with 50 patients (31%) still alive after a median follow-up of 1.74 years. Time-discrete mortality was highest during the first 24h. There was no difference between survivors and non-survivors regarding age, etiology of circulatory failure, presence of CPR during implantation or distance to implantation site. Incidence of kidney injury requiring dialysis (61% vs. 24%, p<0.0001), shock liver (27% vs. 12%, p=0.031) and visceral ischemia (19% vs. 3%, p=0.013) were the only complications increased in non-survivors. Subgroup analysis showed no significant outcome difference for ECPR vs. non-ECPR patients. Outcome was significantly impaired with initial neuron-specific enolase ≥45.4μg/L (AUC 0.75, p<0.0001) and lactate ≥5.5mmol/L (AUC 0.70, p<0.0001). Program-year-dependent in-center mortality showed an increasing trend, while program-year-dependent follow-up mortality decreased over time.
CONCLUSIONS: This study illustrates that regional mobile ECLS rescue therapy can be provided with encouraging outcomes, although patient selection criteria and early outcome parameters reflecting on therapy success or futility still need to be refined.
参考来源
- Aubin H, Petrov G, Dalyanoglu H, et al. Four-year experience of providing mobile extracorporeal life support to out-of-center patients within a suprainstitutional network-Outcome of 160 consecutively treated patients. Resuscitation. 2017. PMID: 28870718. doi:10.1016/j.resuscitation.2017.08.237
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。